Sagene Pharmaceuticals is a biopharmaceutical company founded in 2010 that focuses on developing innovative applications for combinations of FDA-approved drugs to address age-related diseases. The company has demonstrated the potential of selective MAO-B inhibitors, particularly selegiline (l-deprenyl), to enhance the effectiveness and minimize side effects of current treatments for conditions such as erectile dysfunction (ED), pulmonary arterial hypertension (PAH), pain/inflammation, and cardiovascular diseases. Sagene's approach involves targeting multiple disease pathways that are typically not addressed by existing drugs.
Operating in the Biotechnology and Health Care industries, Sagene Pharmaceuticals distinguishes itself through its unique strategy of repurposing FDA-approved medications to meet the needs of an aging population.
Despite providing insightful details about its innovative drug combinations and disease-targeting approach, the company's headquarters location and specific investment information are not currently available. For more information about Sagene Pharmaceuticals, interested parties can visit the company's website at http://sagenepharma.com/.
We care about your data, and we'd love to use cookies make your experience better.